Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs

Background: The MEK (mitogen-activated protein kinase)–inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC). We aimed to analyse the effect of selumetinib on the expression of so...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Mol Sci
Asıl Yazarlar: Wächter, Sabine, Wunderlich, Annette, Greene, Brandon H., Roth, Silvia, Elxnat, Moritz, Fellinger, Sebastian A., Verburg, Frederik A., Luster, Markus, Bartsch, Detlef K., Di Fazio, Pietro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073679/
https://ncbi.nlm.nih.gov/pubmed/30018229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19072077
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller